Sexually Transmitted HCV Superinfection in 2 Patients With HIV/HCV-Coinfection
 |
|
2 cases of HCV superinfection resulting from sexual transmission identified by phylogenetic analysis in HIV/HCV-coinfected men who have sex with men
Format: Microsoft PowerPoint (.ppt) | File size: 329 KB | Date posted: 6/18/2008
Slide topics include:
|
Browse Slides by Date - Descending
The Role of Integrase Inhibitors in HIV Management
 |
|
Martin Markowitz, MD, presents findings on the function of integrase and the role of integrase inhibitors in the management of HIV disease.
Format: Microsoft PowerPoint (.ppt) | File size: 1,471 KB | Date posted: 6/13/2008
Slide topics include:
|
Low-Level Viremia Frequent and Transient, Usually Not Requiring Change in Therapy Due to Low Incidence of Clinical and Immunologic Complications
 |
|
In an observational study, approximately 30% of patients who had achieved undetectable HIV-1 RNA subsequently experienced transient viremia, but low-level viremia was not associated with clinical events, development of high-level viremia, or changes in CD4+ cell counts
Format: Microsoft PowerPoint (.ppt) | File size: 214 KB | Date posted: 6/12/2008
Slide topics include:
|
MONARK Study: Lopinavir/Ritonavir Monotherapy Less Effective Than Standard Triple Therapy Regimen in Antiretroviral-Naive HIV Patients
 |
|
In a randomized, open-label trial, lopinavir/ritonavir monotherapy did not achieve similar virologic response rates overall to standard triple-therapy containing NRTIs, but a subset of patients achieving early virologic response may benefit from simplified therapy
Format: Microsoft PowerPoint (.ppt) | File size: 278 KB | Date posted: 6/12/2008
Slide topics include:
|
Didanosine-Based Antiretroviral Therapy and Failure to Achieve SVR Associated With Fibrosis Progression in HIV/HCV-Coinfected Patients
 |
|
In a retrospective analysis, receipt of didanosine-based therapy and failure to achieve SVR to HCV therapy were the only baseline factors significantly associated with rapid progression of liver disease in multivariate analysis
Format: Microsoft PowerPoint (.ppt) | File size: 204 KB | Date posted: 6/11/2008
Slide topics include:
|
Improved Renal Function With Antiretroviral-Mediated HIV-1 Suppression in Patients With Low CD4+ Cell Count and Advanced Chronic Kidney Disease
 |
|
In a prospective, multicenter study, HIV-1 RNA suppression improved renal function in patients with ≥ stage II chronic kidney disease and baseline CD4+ cell counts < 200 cells/mm3
Format: Microsoft PowerPoint (.ppt) | File size: 207 KB | Date posted: 6/10/2008
Slide topics include:
|
Increasing Incidence of Non-AIDS–Defining Cancers in Cohort of HIV-Infected Patients
 |
|
In a retrospective analysis of malignancies in an urban HIV cohort, the incidence of non-AIDS–defining cancers increased since the introduction of HAART while the incidence of AIDS-defining cancers decreased
Format: Microsoft PowerPoint (.ppt) | File size: 218 KB | Date posted: 6/6/2008
Slide topics include:
|
Prospective HLA-B*5701 Testing Prevents Abacavir-Related Hypersensitivity Reactions
 |
|
In a prospective, randomized, double-blind trial, screening for the HLA-B*5701 allele prior to abacavir use eliminated immunologically confirmed hypersensitivity reactions
Format: Microsoft PowerPoint (.ppt) | File size: 215 KB | Date posted: 6/6/2008
Slide topics include:
|
PISCIS Cohort Illuminates Risk of Progression to AIDS or Death Associated With HCV Coinfection, Potential Benefit of Starting Treatment With CD4+ Count > 350 cells/mm3
 |
|
In addition to documenting an increased risk of disease progression or death in HCV-coinfected patients, PISCIS cohort data demonstrated significantly reduced risk of progression to AIDS in patients who initiated HAART with CD4+ cell counts 350-500 cells/mm3 compared with 200-350 cells/mm3.
Format: Microsoft PowerPoint (.ppt) | File size: 274 KB | Date posted: 6/4/2008
Slide topics include:
|
Expert Viewpoint: How Many Agents Does a Treatment-Experienced Patient Need?
 |
|
Use this PowerPoint Resource to accompany the presentation by W. David Hardy, MD, on determining the number of active agents for the treatment-experienced patient.
Format: Microsoft PowerPoint (.ppt) | File size: 508 KB | Date posted: 5/23/2008
Slide topics include:
|
New This Month: New Data on Abacavir and Implications for Treatment
 |
|
This resource slideset accompanies the presentation by our Program Directors, Kathleen E. Squires, MD; Kimberly Y. Smith, MD, MPH; and Andrew R. Zolopa, MD
Format: Microsoft PowerPoint (.ppt) | File size: 341 KB | Date posted: 5/23/2008
Slide topics include:
|
|
Use the following filters to quickly browse and download slides for your talks
Browse slides by:
All Slides by Date (271)
Program Type
Topic
Featured Content
Join Kimberly Y. Smith, MD, MPH for the inaugural episode of this CME-Certified Podcast series.
Capsule Summaries and Expert Highlights on the key studies. Coming soon: Expert Analyses and slides.
Interact with Eric S. Daar, MD, in a new Virtual Presentation of clinical case scenarios.
|
|